A5064797858- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Immunodeficiency and Autoimmune Disorders
- Monoclonal and Polyclonal Antibodies Research
- Glycosylation and Glycoproteins Research
- Acute Lymphoblastic Leukemia research
- PARP inhibition in cancer therapy
- Calcium signaling and nucleotide metabolism
- Advanced Breast Cancer Therapies
- Immune Cell Function and Interaction
- Prostate Cancer Treatment and Research
- Phagocytosis and Immune Regulation
- Lipoproteins and Cardiovascular Health
- Galectins and Cancer Biology
- Biochemical and Molecular Research
- Chronic Myeloid Leukemia Treatments
- Retinoids in leukemia and cellular processes
- Immunotherapy and Immune Responses
- Cell death mechanisms and regulation
- Biosimilars and Bioanalytical Methods
- Cytomegalovirus and herpesvirus research
- Semiconductor Lasers and Optical Devices
- Telomeres, Telomerase, and Senescence
- Single-cell and spatial transcriptomics
- vaccines and immunoinformatics approaches
Feinstein Institute for Medical Research
2008-2022
Northwell Health
2006-2022
Janssen (United States)
2015-2022
UPMC Hillman Cancer Center
2018
Fred Hutch Cancer Center
2018
University of Pittsburgh Medical Center
2018
Springhouse
2015-2016
Kurume University
2013
Boston University
2013
University of Massachusetts Chan Medical School
2013
Due to its relatively slow clinical progression, B cell chronic lymphocytic leukemia (B-CLL) is classically described as a disease of accumulation rather than proliferation. However, evidence for various forms clonal evolution suggests that B-CLL clones may be more dynamic previously assumed. We used nonradioactive, stable isotopic labeling method measure kinetics in vivo. Nineteen patients drank an aliquot deuterated water (2H2O) daily 84 days, and 2H incorporation into the deoxyribose...
Previous studies suggest that the diversity of expressed variable (V) region repertoire immunoglobulin (Ig)H chain B-CLL cells is restricted. Although limited examples marked constraint in primary structure H and L V regions exist, possibility this level restriction a general principle disease has not been accepted. This report describes five sets patients, mostly with unmutated or minimally mutated IgV genes, strikingly similar B cell antigen receptors (BCRs) arising from use common gene...
Abstract The failure of chemotherapeutic regimens to eradicate cancers often results from the outgrowth minor subclones with more dangerous genomic abnormalities or self-renewing capacity. To explore such intratumor complexities in B-cell chronic lymphocytic leukemia (CLL), we measured kinetics vivo by quantifying deuterium ( 2 H)-labeled cells as an indicator a cell that had divided. Separating CLL clones on basis reciprocal densities chemokine (C-X-C motif) receptor 4 (CXCR4) and cluster...
Purpose The Bruton's tyrosine kinase inhibitor ibrutinib has demonstrated clinical activity in B-cell malignancies. DAWN study assessed the efficacy and safety of single-agent chemoimmunotherapy relapsed/refractory follicular lymphoma (FL) patients. Methods was an open-label, single-arm, phase II patients with FL two or more prior lines therapy. Patients received 560 mg daily until progressive disease/unacceptable toxicity. primary objective independent review committee-assessed overall...
Background The levels and clinical relevance of Th17 cells other interleukin-17-producing have not been analyzed in chronic lymphocytic leukemia. objective this study was to quantify blood tissue patients with disease correlate outcome.Design Methods Intracellular interleukin-17A assessed splenic mononuclear from leukemia healthy subjects using flow cytometry. Interleukin-17A-producing were formalin-fixed, paraffin-embedded spleen lymph node sections immunohistochemistry...
While many prognostic markers in B-cell chronic lymphocytic leukemia provide insight into the biology of disease, few have been demonstrated to be useful daily management patients. receptor signaling is a driving event progression and responsiveness shown value. Single cell network profiling, multiparametric flow cytometry-based assay, allows functional analysis at level single cell. proteins (i.e. p-SYK, p-NF-κB p65, p-ERK, p-p38, p-JNK) were functionally characterized by profiling samples...
Due to its relatively slow clinical progression, B cell chronic lymphocytic leukemia (B-CLL) is classically described as a disease of accumulation rather than proliferation. However, evidence for various forms clonal evolution suggests that B-CLL clones may be more dynamic previously assumed. We used nonradioactive, stable isotopic labeling method measure kinetics in vivo. Nineteen patients drank an aliquot deuterated water (2H2O) daily 84 days, and 2H incorporation into the deoxyribose...
We previously showed that approximately 60% of B chronic lymphocytic leukaemia (B-CLL) cells express surface CD180, an orphan receptor the Toll-like family. Here we investigated ability anti-CD180 monoclonal antibody (mAb) to induce activation, cell cycling, survival and signalling in B-CLL normal cells. Upon addition mAb, alone or combination with anti-CD40 mAb recombinant IL-4 (rIL-4), expression CD86, Ki-67, uptake DiOC(6) , phosphorylation protein kinases Ca(2+) flux were measured from...
One aim of this session given at the Torino CD38 Meeting in June, 2006 was to review role B-cell Chronic Lymphocytic Leukemia (B-CLL), and its potential as a therapeutic target. CD38high B-CLL cases show activated phenotypic features compared with CD38low cases. Moreover, greater percentage Ki-67 telomerase activity is documented among Also, not merely negative prognostic marker B-CLL, but also key element pathogenetic network underlying disease. A large series investigating expression on...